COSCIENS Biopharma Inc. Common Stock
CSCI
CSCI was delisted on the 3rd of September, 2025.
29 hedge funds and large institutions have $318K invested in COSCIENS Biopharma Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 4 increasing their positions, 8 reducing their positions, and 2 closing their positions.
300% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 2
26% more funds holding
Funds holding: 23 → 29 (+6)
0% more ownership
Funds ownership: 0.01% → 0.01% (+0%)
50% less capital invested
Capital invested by funds: $631K → $318K (-$313K)
50% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 8
79% less call options, than puts
Call options by funds: $44K | Put options by funds: $209K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$61.7K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$43.9K |
| 3 |
Millennium Management
New York
|
+$25.7K |
| 4 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
+$10K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$10K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$62K |
| 2 |
VF
Virtu Financial
New York
|
-$21.6K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$7.16K |
| 4 |
Two Sigma Advisers
New York
|
-$5.71K |
| 5 |
JP Morgan Chase
New York
|
-$3.63K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Citigroup
New York
| $1K | +$976 | +39 | New |
|
27
Bank of America
Charlotte,
North Carolina
| $1K | +$1.25K | +50 | New |
|
28
Bank of Montreal
Toronto,
Ontario, Canada
| $2 | -$601 | -24 | -19% |
|
|
29
Renaissance Technologies
New York
| – | -$62K | -1,676 | Closed |
|
30
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$25 | -1 | Closed |
|
CSCI Hedge Fund Activity: Q2 2022 in Review
29 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in COSCIENS Biopharma Inc. Common Stock (CSCI) for Q2 2022, worth a combined $318K — down 50% from $631K a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new CSCI positions and 2 closed out — a net gain of 6 holders — while 4 added to existing stakes and 8 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $61.7K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $62K sold.
- 29 institutional investors held COSCIENS Biopharma Inc. Common Stock (CSCI) as of Q2 2022, up from 23 in Q1 2022.
- Funds reported $318K of COSCIENS Biopharma Inc. Common Stock stock for Q2 2022, down 50% quarter-over-quarter.
- 8 funds opened new COSCIENS Biopharma Inc. Common Stock positions in Q2 2022 and 2 closed out, a net change of +6 holders.
- The largest COSCIENS Biopharma Inc. Common Stock buyer in Q2 2022 was Morgan Stanley, an estimated $61.7K added.
- The largest COSCIENS Biopharma Inc. Common Stock seller in Q2 2022 was Renaissance Technologies, an estimated $62K sold.
Based on aggregated 13F filings for Q2 2022.